Blood Product Derivative; Immune Globulin
CCP: Guillain-Barré, Lambert-Eaton myasthenia gravis, myasthenia gravis, immune thrombocytopenia, Kawasaki syndrome
CCP: Immune thrombocytopenia
CCP: Guillain-Barré
CCP: Lambert-Eaton myasthenia gravis
CCP: Myasthenia gravis
CCP: Immune thrombocytopenia
CCP: Guillain-Barré
CCP: Myasthenia gravis
CCP: Kawasaki disease
Pooled human immune globulins for replacement therapy in primary and secondary immunodeficiencies, and IgG antibodies against bacteria, viral, parasitic and mycoplasma antigens. IVIG may interfere with Fc receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP. Provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential.
Onset of action: IV: Provides immediate antibody levels.
Initial response: 1 to 3 days
Peak response: 2 to 7 days
Half-life: Variable: 14-24 days
Duration: IM, IV: Immune effect: 3 to 4 weeks
Cardiovascular:
Dermatologic:
Endocrine & metabolic:
Gastrointestinal:
Genitourinary:
Hematologic & oncologic:
Hepatic:
Immunologic:
Local:
Nervous system:
Neuromuscular and skeletal:
Respiratory:
Miscellaneous: